Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C

Huang, Yue; Jen, C.-L.; Yang, Hwai I.; Lee, Hsuan-Shu; Su, Jun; Lu, Sheng; Iloeje, Uchenna H.; Chen, Chien Jen

doi:10.1200/jco.2011.36.2335

Cited by 192 publications

(136 citation statements)

References 36 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Other etiologies for liver cancer are modifiable risk factors, such as smoking, alcohol, contaminated injections in health care centers, immigration and obesity (Chuang et al, 2009;Ezzati and Riboli, 2013;Franceschi and Wild, 2013;Shih et al, 2012). The relative risk associated with family history of liver cancer is 2.6 and the cancer is also significantly more common in men (Huang et al, 2011;Yang et al, 2014).…”

Section: Incidence and Mortality Of Liver Cancer In The Wordmentioning

confidence: 99%

Incidence and mortality of liver cancer and their relationship with the human development index in the world

Arabsalmani¹,

Mirzaei²,

Ghoncheh³

et al. 2016

Biomed Res Ther

View full text Add to dashboard Cite

Abstract-Background: Information on the incidence and mortality of liver cancer can be useful for health programs and research activities, and with regard to the possible role of the HDI and liver cancer, this study aimed to investigate incidence and mortality from the cancer and their relationship with the indicator and its components in 2012 in world. Methods: In this ecologic study, data were extracted from GLOBOCAN in 2012. Data on HDI and its components were extracted from the World Bank. The number and standardized incidence and mortality rates of liver cancer were reported by regions in the world. Data were analyzed by SPSS software and Correlation coefficient test. Results: There was a total of 782,451 incidence cases. Of these patients, 228, 082 cases (29.15 %) were women and 554, 369 cases (70.85 %) men, and there were 745,533 deaths. Of the deaths, 224, 492 cases (30.11 %) occurred in women and 521, 041 cases (69.89 %) men were recorded in the world in 2012. Results showed that there was a significant inverse correlation between age-specific incidence rate (ASIR) and HDI (r=-0.345, p≤0.001), as well significant inverse correlation was seen between age-specific mortality rate (ASMR), and HDI and its components. Conclusion: Liver cancer incidence and mortality are higher in the medium HDI countries. The relationship between the standardized incidence and mortality of liver cancer with HDI and its components, including life expectancy at birth, mean years of schooling and income level per person was significantly negative.

show abstract

Section: Incidence and Mortality Of Liver Cancer In The Wordmentioning

confidence: 99%

Incidence and mortality of liver cancer and their relationship with the human development index in the world

Arabsalmani¹,

Mirzaei²,

Ghoncheh³

et al. 2016

Biomed Res Ther

View full text Add to dashboard Cite

show abstract

“…In Western countries, nonviral etiology (such as alcoholism or NAFLD) is the main cause of liver cirrhosis and the HCC incidence is low 1, 2, 3, 4. In Taiwan, hepatitis B virus (HBV) infection is a major risk factor for HCC 5, 6, 7, 8, 9. As of 2015, HCC still ranked second among the leading causes of cancer‐related death in men in Taiwan,10 and researchers have estimated that 80% of HCC cases in Taiwan are related to chronic viral hepatitis 5, 6, 7, 8, 9.…”

mentioning

confidence: 99%

“…In Taiwan, hepatitis B virus (HBV) infection is a major risk factor for HCC 5, 6, 7, 8, 9. As of 2015, HCC still ranked second among the leading causes of cancer‐related death in men in Taiwan,10 and researchers have estimated that 80% of HCC cases in Taiwan are related to chronic viral hepatitis 5, 6, 7, 8, 9. In 1984, Taiwan became the first country in the world to establish a universal HBV vaccination program for newborns/infants 11, 12.…”

mentioning

confidence: 99%

Metabolic risk factors are associated with non‐hepatitis B non‐hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B

Huang

Chang

Hong

et al. 2018

Hepatology Communications

View full text Add to dashboard Cite

Metabolic risk factors, such as obesity, fatty liver, high lipidemia, and diabetes mellitus are associated with increased risk for nonviral hepatocellular carcinoma (HCC); however, few nonviral HCC studies have stratified patients according to underlying etiologies. From 2005 to 2011, 3,843 patients with HCC were recruited into the Taiwan Liver Cancer Network. Of these patients, 411 (10.69%) who were negative for hepatitis B virus (HBV), surface antigen, HBV DNA, and anti‐hepatitis C virus (HCV) antibody were classified as non‐HBV non‐HCV (NBNC)‐HCC. Detailed clinical analyses of these patients were compared with age‐ and sex‐matched patients with HBV‐HCC or HCV‐HCC for the associated metabolic risk factors. For this comparison, 420 patients with HBV‐HCC and 420 patients with HCV‐HCC were selected from the 3,843 patients with HCC. Multivariate analyses showed fatty liver (by echography), high triglyceride levels (>160 mg/dL), and diabetes mellitus history to be significantly associated only with NBNC‐HCC and not with the matched patients with HBV‐ or HCV‐HCC. When the patients with HCC were further divided into four groups based on history of alcoholism and cirrhotic status, the group without alcoholism and without cirrhosis exhibited the strongest association with the metabolic risk factors. Based on trend analyses, patients with NBNC‐HCC with or without alcoholism were significantly different from the matched patients with HBV‐ or HCV‐HCC, except for patients with alcoholism and cirrhosis, in having more than two of the above three risk factors. Conclusion: Metabolic risk factors are significantly associated with nonviral HCC, especially for patients without alcoholism in Taiwan. Because the prevalence of viral HCC is decreasing due to the success of universal vaccination and antiviral therapy, strategies for cancer prevention, prediction, and surveillance for HCC will require modification. (Hepatology Communications 2018;2:747‐759)

show abstract

“…[3][4][5][6][7] Consequently, this group of patients needs to be treated more actively. In patients with HCV genotype 1 infection, the rate of sustained virologic response (SVR) at 24 weeks (SVR24) after the end of combination therapy with peginterferon alfa-2a and ribavirin was 72.2% in coinfected patients versus 77.3% in monoinfected patients; for patients with HCV genotype 2/3 infection, the SVR24 values were 82.8% and 84.0%, respectively.…”

mentioning

confidence: 99%

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Lee

Chen

et al. 2013

Hepatology

Self Cite

View full text Add to dashboard Cite

Patients dually infected with hepatitis C virus (HCV)/hepatitis B virus (HBV) have a higher risk of developing advanced liver disease or hepatocellular carcinoma compared with monoinfected patients. Yet, there is a similar rate of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy in these patients compared with HCVmonoinfected patients and a high hepatitis B surface antigen (HBsAg) seroclearance rate. The durability of hepatitis C and B clearance in coinfected patients was investigated in a 5-year follow-up study. Patients with active HCV genotype 1, both HBV-coinfected (n 5 97) and HBVmonoinfected (n 5 110), underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin. In patients with active HCV genotype 2 or 3, both HBV-coinfected (n 5 64) and monoinfected (n 5 50) patients underwent 24-week combination therapy. A total of 295 (91.9%) patients completed treatment and 24 weeks posttreatment follow-up; 264 (89.5%) patients agreed to receive additional follow-up for up to 5 years after the end of treatment. After a median follow-up of 4.6 6 1.0 years, six of the 232 patients achieving SVR developed HCV RNA reappearance, including five HCV genotype 1/HBV-coinfected patients and one HCV genotype 2/3-monoinfected patient. Subgenomic analysis of the HCV core gene indicated that five patients developed delayed recurrence of HCV infection. Overall, the cumulative recurrence rate of HCV infection was 2.3% (0.4%/year; 95% confidence interval [CI], 0.9%-5.5%). The cumulative HBsAg seroclearance rate was 30.0% (95% CI, 21.5%-42.0%); with 33.1% (95% CI, 21.8%-50.1%) in the 48-week combination therapy group and 24.3% (95% CI, 13.7%-42.9%) in the 24-week therapy group. Conclusion: Peginterferon alfa-2a and ribavirin therapy provides good HCV SVR durability and a high accumulative HBsAg seroclearance rate in patients who are coinfected with HCV and HBV. (HEPATOLOGY 2013;57:2135-2142

show abstract

Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C

Cited by 192 publications

References 36 publications

Incidence and mortality of liver cancer and their relationship with the human development index in the world

Incidence and mortality of liver cancer and their relationship with the human development index in the world

Metabolic risk factors are associated with non‐hepatitis B non‐hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Contact Info

Product

Resources

About